Diabetic Foot Ulcer (DFU) Market & Drug Pipeline Analysis - Forecast to 2025

Publishing Date : December, 2018
Report Code : HCPH0001
Single license $4,950
Site license $6,750
Global license $9,000

Note: The report would be dispatched after confirmation of payment

“Diabetic Foot Ulcer (DFU) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of DFU. The report covers all the drugs that are in various phases of development (Discovery, Preclinical and Clinical). The pipeline focuses on novel pharmacologic drugs and regenerative medicines covering, antibodies, stem cell therapies, recombinant proteins, Peptide therapies, RNA-based therapeutics and others, but excludes symptom relief drugs, wound dressing, drug delivery systems, generic combinations and radiation therapies. The report also covers some of the hot targets in research for DFU treatments and related biomarkers.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the DFU drugs market. The report also provide strategic insights on some of the molecules that are yet to be launched in the next few years. Some of the key sections covered in the report are given below:

DFU Introduction

DFU grading, Treatment algorithm, Patient care pathway & Visiting patterns, Clinical practice guidelines, Current SOC, Adjuvant therapies, Alternative approaches, Unmet needs, ICD/CPT codes


In this section, epidemiology of DFU is reviewed to understand potential significance and impact of the disease.

Global and US prevalence rates

Hot Targets, Pathophysiology and Biomarkers

In this section, various DFU associated targets, pathophysiology, and biomarkers are discussed. Also, covers novel targets in early research for DFU.

Market Data

Forecasting model for DFU market

DFU market dynamics

DFU Market Sizing

DFU related deals & Funding scenario in DFU market

Pipeline Analysis

Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical and development section, pipelines from major companies were identified and potential targets were reported along with Mechanism of action, Current development status and nature of molecule. Pipeline analysis by developmental stage (Discovery to Clinical development).

Small Molecules

Large Molecules

Stem Cell therapies, Protein therapies , Peptide therapies  and Others

Drug analysis based on mechanism (Wound healing,  Neuropathy, Ischemia, Neuroischemia and infection)

Key Players Analysis

The key player’s analysis section provides an in-depth understanding of various companies working on DFU and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.

Global key players overview

Global key players Pipeline data (Discovery, Pre-clinical and Clinical development)

Global key players deals (Collaborations, Licensing, Service agreements, grants, funds)

  • 2     SUMMARY
    • 3.1     Epidemiology
    • 3.2     Causes, Symptoms and Risk Factors
    • 3.3     Grading Systems
    • 3.4     Diagnosis and Management
    • 3.5     Algorithm for DFU Treatment
    • 3.6     Care Pathways and Patient Visiting Patterns
    • 3.7     Clinical Practice Guidelines
    • 3.8     Current Standard of Care
    • 3.9     Adjuvant Therapies
    • 3.10     Alternative Therapeutic Approaches
    • 3.11     Unmet needs
    • 3.12     ICD/CPT codes
    • 4.1     Pathophysiology of DFU
    • 4.2     Leading Targets
    • 4.3     Novel Targets
    • 4.4     Biomarkers
  • 5     MARKET DATA
    • 5.1     Forecasting model
    • 5.2     Market dynamics
    • 5.3     Market sizing
    • 5.4     DFU Deals
    • 5.5     Funding Scenario
    • 5.6     Regulatory Guidelines
    • 5.7     DFU Regulatory Guidelines
    • 6.1     Development stage
    • 6.2     Molecule Type
    • 6.3     Clinical update on Phase 3 molecules
    • 7.1     Pipeline
    • 7.2     Competitive Analysis
    • 8.1     Pipeline
    • 8.2     Competitive Analysis
      • 8.2.1     Stem Cell Therapies
        •     Pipeline
      • 8.2.2     Protein Therapies
        •     Pipeline
      • 8.2.3     Peptide Therapies
        •     Pipeline
        •     Pipeline
      • 8.2.5     OTHER MOLECULES
        •     Pipeline
  • 10     MAJOR PLAYERS
    • 10.1     Company Profiles
      • 10.1.1     Overview
      • 10.1.2     Pipeline
      • 10.1.3     Deals
  • 11     REFERENCES